Patents by Inventor Victor H. Obungu

Victor H. Obungu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20230279098
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20230279094
    Abstract: The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer’s Disease or a tauopathy disease.
    Type: Application
    Filed: October 27, 2022
    Publication date: September 7, 2023
    Inventors: Marcio Chedid, Adam S. Fleisher, Megan Brittany Lannan, Albert Lo, Mark Mintun, Victor H. Obungu, Sarah Elisabeth Raines, John Randall Sims, II, Andrew Dixon Skora, Robin Elizabeth Walsh, Elizabeth Anne West, Ming Ye
  • Antibodies to IL-34
    Patent number: 11649280
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: May 16, 2023
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • Parathyroid hormone-anti-RANKL antibody fusion compounds
    Patent number: 11492386
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • BTLA agonist antibodies and uses thereof
    Patent number: 11396545
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: July 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
    Publication number: 20210363232
    Abstract: The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 25, 2021
    Inventors: Marcio Chedid, Victor H. Obungu, Andrew Dixon Skora, Ming Ye
  • Growth differentiation factor 15 agonist compounds and methods of using the same
    Patent number: 11104711
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 31, 2021
    Assignee: Eli Lilly and Company
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • Anti-RANKL antibodies and uses thereof
    Patent number: 10913799
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • PARATHYROID HORMONE-ANTI-RANKL ANTIBODY FUSION COMPOUNDS
    Publication number: 20200354427
    Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.
    Type: Application
    Filed: January 25, 2017
    Publication date: November 12, 2020
    Inventors: Andrew H Korytko, Yanfei L Ma, Amita Datta-Mannan, Victor H Obungu
  • BTLA AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20200239578
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Application
    Filed: February 17, 2020
    Publication date: July 30, 2020
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • BTLA agonist antibodies and uses thereof
    Patent number: 10604573
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 31, 2020
    Assignee: Eli Lilly and Company
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • Anti-Dkk-1-anti-RANKL bispecific antibody compounds
    Patent number: 10584174
    Abstract: Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 10, 2020
    Assignee: Eli Lilly and Company
    Inventors: Victor H Obungu, Andrew Korytko
  • GROWTH DIFFERENTIATION FACTOR 15 AGONIST COMPOUNDS AND METHODS OF USING THE SAME
    Publication number: 20190309033
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 10, 2019
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • ANTI-RANKL ANTIBODIES AND USES THEREOF
    Publication number: 20190284289
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 19, 2019
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • BTLA AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20180334502
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 22, 2018
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • ANTI-DKK-1-ANTI-RANKL BISPECIFIC ANTIBODY COMPOUNDS
    Publication number: 20180118840
    Abstract: Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.
    Type: Application
    Filed: May 12, 2016
    Publication date: May 3, 2018
    Inventors: Victor H Obungu, Andrew Korytko
  • Anti-CXCR4 antibodies
    Patent number: 8003102
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: August 23, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20110086027
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: December 17, 2010
    Publication date: April 14, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • Anti-CXCR4 antibodies
    Patent number: 7892546
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: February 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt
  • ANTI-CXCR4 ANTIBODIES
    Publication number: 20100285005
    Abstract: The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.
    Type: Application
    Filed: May 7, 2009
    Publication date: November 11, 2010
    Inventors: Cindy Takeuchi Dickerson, David Matthew Marquis, Victor H. Obungu, Sheng-Bin Peng, Peter Edward Vaillancourt